NYSEAMERICAN:CATX

Perspective Therapeutics (CATX) Stock Price, News & Analysis

Perspective Therapeutics logo
$0.92 -0.02 (-2.05%)
Closing price 04:10 PM Eastern
Extended Trading
$0.95 +0.02 (+2.51%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Perspective Therapeutics Stock (NYSEAMERICAN:CATX)

Advanced

Key Stats

Today's Range
$0.90
▼
$1.02
50-Day Range
$0.79
▼
$3.13
52-Week Range
$0.78
▼
$6.16
Volume
2.30 million shs
Average Volume
2.41 million shs
Market Capitalization
$111.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.10
Consensus Rating
Moderate Buy

Company Overview

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue.

The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors. These products are in clinical development and are not approved for general use.

Perspective also works on producing lead-212 for its research and development programs. The company traces its roots to IsoRay, which developed cesium-131 brachytherapy products, and adopted the Perspective Therapeutics name following a 2023 merger with Viewpoint Molecular Targeting.

AI Generated. May Contain Errors.

Perspective Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

CATX MarketRank™: 
4.60758318971 of 5 stars

Perspective Therapeutics scored higher than 92% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Perspective Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Perspective Therapeutics has a consensus price target of $10.10, representing about 990.7% upside from its current price of $0.93.

  • Amount of Analyst Coverage

    Perspective Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Perspective Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Perspective Therapeutics are expected to decrease in the coming year, from ($1.01) to ($1.10) per share.

  • Price to Book Value per Share Ratio

    Perspective Therapeutics has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.10% of the float of Perspective Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Perspective Therapeutics has a short interest ratio ("days to cover") of 2.47, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Perspective Therapeutics has recently decreased by 46.19%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Perspective Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Perspective Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Perspective Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Perspective Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for CATX on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • Cluster Insider Buying

    5 insiders have purchased shares of Perspective Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $128,314.00 in company stock, which represents 0.1147% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $128,314.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    2.99% of the stock of Perspective Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Perspective Therapeutics' insider trading history.
Receive CATX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CATX Stock News Headlines

FY2026 EPS Estimate for Perspective Therapeutics Decreased by Analyst
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Perspective Therapeutics (CATX) Gets a Buy from BMO Capital
See More Headlines

CATX Stock Analysis - Frequently Asked Questions

Perspective Therapeutics' stock was trading at $2.75 at the beginning of the year. Since then, CATX stock has decreased by 66.3% and is now trading at $0.9260.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) released its quarterly earnings data on Monday, November, 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.03. The company had revenue of $20 thousand for the quarter, compared to analysts' expectations of $56 thousand. Perspective Therapeutics had a negative trailing twelve-month return on equity of 42.25% and a negative net margin of 55,866.82%.

Perspective Therapeutics shares reverse split on the morning of Monday, June 17th 2024.The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional shareholders of Perspective Therapeutics include Nantahala Capital Management LLC (2.06%), State Street Corp (1.68%), Marshall Wace LLP (1.23%) and Voya Investment Management LLC (0.40%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Markus Puhlmann, Robert F Williamson III, Johan M Spoor, Jonathan Robert Hunt, Juan Graham, Lori A Woods, Heidi Henson and Frank Morich.
View institutional ownership trends
.

Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Perspective Therapeutics investors own include NVIDIA (NVDA), Larimar Therapeutics (LRMR), Definium Therapeutics (DFTX), Immunic (IMUX), Palantir Technologies (PLTR), Marvell Technology (MRVL) and Intel (INTC).

Company Calendar

Last Earnings
11/09/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSEAMERICAN:CATX
Previous Symbol
NYSE:CATX
CIK
728387
Employees
166
Year Founded
N/A

Price Target and Rating

High Price Target
$14.00
Low Price Target
$4.00
Potential Upside/Downside
+993.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$103.12 million
Net Margins
-55,866.82%
Pretax Margin
-56,316.82%
Return on Equity
-42.25%
Return on Assets
-34.53%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
5.18
Quick Ratio
5.18

Sales & Book Value

Annual Sales
$880 thousand
Price / Sales
126.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.79 per share
Price / Book
0.33

Miscellaneous

Outstanding Shares
120,760,000
Free Float
117,148,000
Market Cap
$111.56 million
Optionable
Optionable
Beta
2.03
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSEAMERICAN:CATX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners